Effect of recombinant human erythropoietin in preterm infants (Journal article)

Krallis, N./ Cholevas, V./ Mavridis, A./ Georgiou, I./ Bourantas, K./ Andronikou, S.

Twenty-five premature infants (mean gestational age+/-SD, 31.4+/-1.9 weeks) were administered subcutaneously recombinant human erythropoietin (rHuEpo) at a dose of 300 u/kg of body weight three times a week beginning on the third day of life and continuing for 6 weeks. The controls (n=23) were premature infants with a mean gestational age of 32.2+/-2.3 weeks who did not receive rHuEpo. Haematological indices, haemoglobin and serum phosphate (Pi), and red blood cell (RBC) phosphate metabolites (ATP, 2,3-DPG, RBCPi) were tested monthly until the 6th month and thereafter at the 9th and 12th months of life. The level of serum soluble transferrin receptors (sTfR) correlated significantly with rHuEpo (p<0.05). The ratio of sTfR to log (ferritin) was significantly higher (p<0.001) in the infants treated with rHuEpo than the controls. Intracellular organic and inorganic Pi changes were not affected by the Epo administration. The RBC 2,3-DPG seemed adequate in infants receiving rHuEpo.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: 2,3-Diphosphoglycerate/blood,Adenosine Triphosphate/blood,Anemia/drug therapy/*prevention & control,Energy Metabolism,Erythrocytes/*metabolism,Erythropoietin/blood/*therapeutic use,Follow-Up Studies,Gestational Age,Humans,Infant, Newborn,*Infant, Premature,Phosphates/*blood,Prospective Studies,Receptors, Transferrin/blood,Recombinant Proteins,Treatment Outcome
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/22174
ISSN: 0902-4441
Link: http://www.ncbi.nlm.nih.gov/pubmed/10480285
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.